## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($181.24)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Arrowstreet Capital Limited Partnership Buys New Shares in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251207T010924 | Somewhat-Bullish | Relevance: 99%
-  Arrowstreet Capital Limited Partnership acquired a new position of 197,345 shares in Becton, Dickinson & Company (NYSE:BDX) during Q2, valued at approximately $33.99 million. Other institutional investors also adjusted their holdings in BDX, which currently has a "Hold" consensus rating from analysts with a price target of $204.45. Becton, Dickinson and Company also increased its quarterly dividend to $1.05 per share, resulting in an annualized dividend of $4.20.

**2. Is Becton Dickinson (BDX) Quietly Reframing Its Moat Around Everyday Hospital Safety Workflows?**
- Source: Simply Wall Street | 20251207T124441 | Somewhat-Bullish | Relevance: 98%
-  Becton Dickinson (BDX) is enhancing its position in hospital safety workflows through a new collaboration with ChemoGLO, integrating rapid hazardous drug testing with detailed lab analysis. This move aligns with BD's broader strategy of combining its installed base of medical consumables with innovation, including investments in Biosciences tools despite an upcoming segment separation. The company projects significant revenue and earnings growth, though investors should consider execution risks associated with the separation and varying fair value estimates within the investment community.

**3. Is Becton Dickinson (BDX) Quietly Reframing Its Moat Around Everyday Hospital Safety Workflows?**
- Source: Simply Wall Street | 20251207T130720 | Somewhat-Bullish | Relevance: 98%
-  Becton Dickinson (BD) recently announced a collaboration with ChemoGLO, integrating BD’s rapid hazardous drug tests with ChemoGLO’s lab analysis to improve hospital staff safety. This move aligns with BD’s strategy to embed its safety technologies deeper into hospital workflows and supports its "reset-and-separation" investment narrative. While the company focuses on innovation and a complex Biosciences and Diagnostics separation, investors should consider execution risks and various fair value estimates.

**4. First Trust Advisors LP Has $47.38 Million Position in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251209T093323 | Somewhat-Bullish | Relevance: 98%
-  First Trust Advisors LP increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 6.3% during the second quarter, valuing their position at $47.38 million. Other institutional investors like Vanguard Group Inc. and T. Rowe Price Investment Management Inc. also significantly increased their holdings in the medical instruments supplier. The article also details recent insider stock sales, analyst ratings, and the company's financial performance, including a recent dividend increase.

**5. Jump Financial LLC Raises Holdings in Becton, Dickinson and Company $BDX**
- Source: MarketBeat | 20251208T114458 | Somewhat-Bullish | Relevance: 98%
-  Jump Financial LLC significantly increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 4,548.6% in the second quarter, bringing its total holdings to 65,173 shares valued at $11,226,000. Other institutional investors also adjusted their positions, and the company recently declared a quarterly dividend of $1.05 per share. Analysts generally hold a "Hold" rating on BDX with a consensus price target of $204.45.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.97 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $54.1B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.97 |
| Forward P/E | 11.9 |
| Current P/E | 12.6 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -2.5% (minimal 5-day change). Below STRENGTH zone by 5.5pp (needs >3.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. RSI neutral at 48.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.53% (CS: 30) | Weak |
| RSI_14 | 47.5 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 0.989x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $188.82
- **Stop Loss:** $181.24 (4.0% risk)
- **Target:** $196.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $7,363.98
- **Portfolio %:** 7.36%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*